BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30220489)

  • 1. [Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].
    Faviez G; Bousquet E; Rabeau A; Rouquette I; Collot S; Goumarre C; Meyer N; Prevot G; Mazieres J
    Rev Mal Respir; 2018 Nov; 35(9):963-967. PubMed ID: 30220489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
    Cabanié C; Ammari S; Hans S; Pobel C; Laparra A; Danlos FX; Chanson N; Dolidon S; Seban R; Voisin AL; Pautier P; Romano-Martin P; Even C; Baldini C; Besse B; Albiges L; Boutros C; Routier E; Balleyguier C; De Montpreville VT; Champiat S; Massard C; Robert C; Marabelle A; Mateus C; Lambotte O; Le Pavec J; Michot JM
    Eur J Cancer; 2021 Oct; 156():46-59. PubMed ID: 34425404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 7. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
    Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
    J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumour assessment criteria for immune checkpoint inhibitors].
    Wasielewski E; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):828-845. PubMed ID: 30166076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.
    Nishino M; Sholl LM; Awad MM; Hatabu H; Armand P; Hodi FS
    Cancer Immunol Res; 2018 Jun; 6(6):630-635. PubMed ID: 29622582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of immunotherapy in older adults: New treatments, new toxicities?
    Helissey C; Vicier C; Champiat S
    J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Toxicities of immune checkpoint inhibitors and their management].
    Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
    Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.